Research Topic · Peer-Reviewed

Covid Variant Treatment

The coronavirus pandemic has been ongoing for over a year, and there have been several variants that have emerged since the beginning of the pandemic. These variants can be more contagious, more deadly, and more resistant to treatment. It is important for scientists to identify new treatments that can target these v…

Curated from this journal's research 📚 10 peer-reviewed articles cited Cited 18× across the literature 🔖 ISSN 2692-1537 🗓 Reviewed June 2026

Overview

The coronavirus pandemic has been ongoing for over a year, and there have been several variants that have emerged since the beginning of the pandemic. These variants can be more contagious, more deadly, and more resistant to treatment. It is important for scientists to identify new treatments that can target these variants and improve patient outcomes. In this article, we will discuss the latest developments in Covid variant treatment. Emergency Use Authorization for Monoclonal Antibodies: Monoclonal antibodies are a type of treatment that can target specific parts of the virus. The US Food and Drug Administration (FDA) recently granted Emergency Use Authorization (EUA) for two monoclonal antibody treatments, casirivimab and imdevimab. These treatments have been shown to reduce hospitalization and death rates in patients with Covid-19, including those infected with certain variants such as the B.1.1.7 (UK) and the P.1 (Brazil) variants. Remdesivir: Remdesivir is an antiviral drug that was initially developed to treat Ebola. It has been repurposed to treat Covid-19 and has been used in hospitalized patients to reduce recovery time. Some studies have also shown that it may be effective against certain variants of the virus, such as the B.1.1.7 (UK) variant. Convalescent Plasma: Convalescent plasma is a treatment that involves using blood plasma from recovered Covid-19 patients to help those who are currently infected with the virus. This plasma contains antibodies that can help fight off the virus. While this treatment has not been shown to be effective against all variants of the virus, it remains a promising option for certain patients. Conclusion: As the Covid-19 pandemic continues to evolve, it is important for researchers to explore new treatment options for patients infected with new variants of the virus. The FDA's Emergency Use Authorization for monoclonal antibodies has been a significant step forward in this effort. Additionally, repurposed drugs like remdesivir and innovative treatments like convalescent plasma offer hope for patients who are currently battling Covid-19. Researchers must continue to explore new treatment options to ensure that patients around the world have access to the best possible care.

Research published in this journal

10 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 10 articles above have been cited 18 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Covid Variant Treatment, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in International Journal of Coronaviruses (ISSN 2692-1537).

Journal editorial board
Dr. Sasho Stoleski · North Macedonia Dr. Amgad M. Rabie · Egypt Dr. Omeed Memar · USA

This page summarises published research for orientation; it is not medical or professional advice.